Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
TB PRACTECAL is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III
trial; evaluating short treatment regimens containing bedaquiline and pretomanid in
combination with existing and re-purposed anti-TB drugs for the treatment of biologically
confirmed pulmonary multi drug-resistant TB (MDR-TB).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medecins Sans Frontieres, Netherlands
Collaborators:
Drugs for Neglected Diseases eResearch Technology, Inc. Global Alliance for TB Drug Development London School of Hygiene and Tropical Medicine Ministry of Health, Republic of Uzbekistan Ministry of Health, Swaziland Ministry of Public Health, Republic of Belarus Rutgers, The State University of New Jersey Swiss Tropical & Public Health Institute THINK TB & HIV Investigative Network University College, London University of California, San Francisco University of Liverpool Wits Health Consortium (Pty) Ltd World Health Organization